Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Change in Receivables (2016 - 2025)

OptimizeRx (OPRX) has disclosed Change in Receivables for 16 consecutive years, with $5.5 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 53.82% to $5.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$460000.0 through Dec 2025, down 121.22% year-over-year, with the annual reading at -$460000.0 for FY2025, 121.22% down from the prior year.
  • Change in Receivables hit $5.5 million in Q4 2025 for OptimizeRx, up from -$1.3 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $12.0 million in Q4 2024 to a low of -$6.4 million in Q1 2024.
  • Historically, Change in Receivables has averaged $756705.4 across 5 years, with a median of $509500.0 in 2023.
  • Biggest five-year swings in Change in Receivables: soared 415.99% in 2023 and later plummeted 2402.64% in 2024.
  • Year by year, Change in Receivables stood at $4.1 million in 2021, then increased by 12.26% to $4.6 million in 2022, then soared by 108.88% to $9.6 million in 2023, then increased by 25.25% to $12.0 million in 2024, then tumbled by 53.82% to $5.5 million in 2025.
  • Business Quant data shows Change in Receivables for OPRX at $5.5 million in Q4 2025, -$1.3 million in Q3 2025, and $792000.0 in Q2 2025.